共 50 条
- [31] A PD-1 polymorphism is associated with disease progression in multiple sclerosisANNALS OF NEUROLOGY, 2005, 58 (01) : 50 - 57Kroner, AMehling, MHemmer, BRieckmann, PToyka, KVMäurer, MWiendl, H
- [32] Exploring immune checkpoint inhibitors: Focus on PD-1/PD-L1 axis and beyondPATHOLOGY RESEARCH AND PRACTICE, 2025, 269Aden, DurreZaheer, SamreenSureka, NitiTrisal, MonalChaurasia, Jai KumarZaheer, Sufian
- [33] Progression-free survival as surrogate endpoint for overall survival in NSCLC trials of anti PD-1 and anti PD-L1 agents and the impact of line of treatment.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Dasgupta, AnandaroopDhingra, NidhiStinchcombe, TomThottassery, Jaideep V.
- [34] Interactions between EGFR and PD-1/PD-L1 pathway: Implications for treatment of NSCLCCANCER LETTERS, 2018, 418 : 1 - 9Li, XueLian, ZhenWang, ShuaiXing, LigangYu, Jinming
- [35] Hyperprogressive Disease in Anorectal Melanoma Treated by PD-1 InhibitorsFRONTIERS IN IMMUNOLOGY, 2018, 9Faure, MarjorieRochigneux, PhilippeOlive, DanielTaix, SebastienBrenot-Rossi, IsabelleGilabert, Marine
- [36] Impact of low serum iron on treatment outcome of PD-1 inhibitors in advanced gastric cancerBMC CANCER, 2023, 23 (01)Yang, YuLi, YaChen, Zhendong
- [37] PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?CLINICAL CANCER RESEARCH, 2020, 26 (20) : 5287 - 5296Khasraw, MustafaReardon, David A.Weller, MichaelSampson, John H.
- [38] A bivalent Tim-3/PD-1 bispecific antibody for the treatment of PD-1 antibody resistant or refractory NSCLC.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Liu, JiajianLuan, Y.Deng, H.Wang, F.Wang, C.Zhang, Z.
- [39] EVIDENCE-BASED VALUE OF PD-1 / PD-L1 INHIBITORS IN NSCLC: COMPARISON OF VALUE TO PRICEVALUE IN HEALTH, 2018, 21 : S91 - S91Doyle, J. J.Wood, B.
- [40] Impact of low serum iron on treatment outcome of PD-1 inhibitors in advanced gastric cancerBMC Cancer, 23Yu YangYa LiZhendong Chen